Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
WVE Stock Forecast 2025-2026
$6.90
Current Price
$1.06B
Market Cap
Buy 12
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to WVE Price Targets
+421.7%
To High Target of $36.00
+204.3%
To Median Target of $21.00
+30.4%
To Low Target of $9.00
WVE Price Momentum
-0.7%
1 Week Change
+5.5%
1 Month Change
+33.7%
1 Year Change
-44.2%
Year-to-Date Change
-58.8%
From 52W High of $16.74
+62.4%
From 52W Low of $4.25
📊 TOP ANALYST CALLS
Did WVE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if WaVe is one of their latest high-conviction picks.
Latest WVE Stock Price Targets & Analyst Predictions
Based on our analysis of 16 Wall Street analysts, WVE has a bullish consensus with a median price target of $21.00 (ranging from $9.00 to $36.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $6.90, the median forecast implies a 204.3% upside. This outlook is supported by 12 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joon Lee at Truist Securities, projecting a 421.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
WVE Analyst Ratings
12
Buy
1
Hold
0
Sell
WVE Price Target Range
Low
$9.00
Average
$21.00
High
$36.00
Current: $6.90
Latest WVE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for WVE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 11, 2025 | Raymond James | Michael Freeman | Outperform | Assumes | $14.00 |
| Apr 29, 2025 | Cantor Fitzgerald | Steven Seedhouse | Overweight | Initiates | $10.00 |
| Mar 26, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $22.00 |
| Mar 5, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $22.00 |
| Feb 25, 2025 | Jefferies | Roger Song | Buy | Initiates | $26.00 |
| Nov 21, 2024 | Mizuho | Salim Syed | Outperform | Maintains | $22.00 |
| Nov 13, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $22.00 |
| Nov 12, 2024 | Truist Securities | Joon Lee | Buy | Maintains | $36.00 |
| Nov 4, 2024 | B. Riley Securities | Madison El-Saadi | Buy | Maintains | $22.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $22.00 |
| Oct 21, 2024 | RBC Capital | Luca Issi | Sector Perform | Maintains | $15.00 |
| Oct 17, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $22.00 |
| Oct 17, 2024 | JP Morgan | Eric Joseph | Overweight | Maintains | $17.00 |
| Oct 16, 2024 | Raymond James | Steven Seedhouse | Strong Buy | Upgrade | $22.00 |
| Oct 16, 2024 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $22.00 |
| Oct 16, 2024 | Leerink Partners | Mani Foroohar | Outperform | Maintains | $22.00 |
| Oct 4, 2024 | RBC Capital | Luca Issi | Sector Perform | Maintains | $7.00 |
| Oct 3, 2024 | B. Riley Securities | Madison El-Saadi | Buy | Maintains | $19.00 |
| Sep 27, 2024 | JP Morgan | Eric Joseph | Overweight | Reinstates | $13.00 |
| Sep 25, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $22.00 |
Wave Life Sciences Ltd. (WVE) Competitors
The following stocks are similar to WaVe based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Wave Life Sciences Ltd. (WVE) Financial Data
Wave Life Sciences Ltd. has a market capitalization of $1.06B with a P/E ratio of -9.9x. The company generates $104.94M in trailing twelve-month revenue with a -107.0% profit margin.
Revenue growth is -26.8% quarter-over-quarter, while maintaining an operating margin of -542.8% and return on equity of -105.5%.
Valuation Metrics
Market Cap
$1.06B
Enterprise Value
$804.14M
P/E Ratio
-9.9x
PEG Ratio
-7.0x
Price/Sales
10.1x
Growth & Margins
Revenue Growth (YoY)
-26.8%
Gross Margin
N/A
Operating Margin
-542.8%
Net Margin
-107.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+22.9%
Current Ratio
3.0x
Debt/Equity
13.1x
ROE
-105.5%
ROA
-30.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Wave Life Sciences Ltd. (WVE) Business Model
About Wave Life Sciences Ltd.
What They Do
Develops stereopure nucleic acid therapies.
Business Model
The company operates in the biotechnology sector, focusing on the research and development of innovative nucleic acid therapies aimed at modulating RNA to treat genetic diseases. Wave Life Sciences generates revenue through the advancement of its therapies, which are designed to be more effective than traditional treatments, potentially allowing for partnerships and licensing agreements with larger pharmaceutical companies.
Additional Information
Wave Life Sciences is positioned as a pioneer in gene medicine, targeting serious diseases and aiming to provide solutions for unmet medical needs. Its research efforts could lead to significant advancements in precision medicine, and the company actively collaborates with various stakeholders in the biopharmaceutical industry to enhance therapeutic development.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
287
CEO
Dr. Paul B. Bolno M.B.A., M.D.
Country
Singapore
IPO Year
2015
Website
wavelifesciences.comWave Life Sciences Ltd. (WVE) Latest News & Analysis
Latest News
Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer
22 days ago
Quick Summary
Wave Life Sciences Ltd. announced news from Cambridge, Mass., on May 28, 2025. Further details were not provided in the excerpt.
Why It Matters
Wave Life Sciences Ltd.'s news could indicate developments in biotech, potentially impacting stock performance and market sentiment in the sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Wave Life Sciences Ltd. announced news from Cambridge, Mass. on May 29, 2025. Further details are necessary for investment decisions.
Why It Matters
Wave Life Sciences Ltd. may indicate developments in biotech, affecting stock performance and investor sentiment in the sector. Watch for product announcements or financial results.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Wave Life Sciences Ltd. will hold its Q1 2025 earnings conference call on May 8, 2025, at 8:30 AM ET, featuring key executives and analysts from various firms.
Why It Matters
The upcoming earnings call for Wave Life Sciences will provide insights into financial performance and strategic direction, impacting investor sentiment and stock price.
Source: Seeking Alpha
Market Sentiment:
Neutral
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
1 month ago
Quick Summary
Dosing in the INLIGHT trial for obesity treatment WVE-007 is complete; data expected by 2H 2025. WVE-006 and WVE-N531 trials are ongoing, with results anticipated in 2025. Cash reserves at $243.1M.
Why It Matters
Positive clinical trial data and upcoming submissions indicate strong potential for WVE-007, WVE-006, and WVE-N531, enhancing investor confidence in the company's growth and financial health.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Wave Life Sciences reported a quarterly loss of $0.29 per share, exceeding the Zacks estimate of $0.27, and worse than a loss of $0.24 per share from the previous year.
Why It Matters
Wave Life Sciences' quarterly loss exceeding estimates indicates potential operational issues, raising concerns about financial health and future performance, impacting investor sentiment and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Wave Life Sciences Ltd. (Nasdaq: WVE) will host a webcast on May 8, 2025, at 8:30 a.m. ET to discuss Q1 2025 financial results and business updates.
Why It Matters
Wave Life Sciences' Q1 2025 financial results and updates may influence investor confidence and stock performance, reflecting the company's progress in RNA medicine development.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About WVE Stock
What is Wave Life Sciences Ltd.'s (WVE) stock forecast for 2025?
Based on our analysis of 16 Wall Street analysts, Wave Life Sciences Ltd. (WVE) has a median price target of $21.00. The highest price target is $36.00 and the lowest is $9.00.
Is WVE stock a good investment in 2025?
According to current analyst ratings, WVE has 12 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for WVE stock?
Wall Street analysts predict WVE stock could reach $21.00 in the next 12 months. This represents a 204.3% increase from the current price of $6.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Wave Life Sciences Ltd.'s business model?
The company operates in the biotechnology sector, focusing on the research and development of innovative nucleic acid therapies aimed at modulating RNA to treat genetic diseases. Wave Life Sciences generates revenue through the advancement of its therapies, which are designed to be more effective than traditional treatments, potentially allowing for partnerships and licensing agreements with larger pharmaceutical companies.
What is the highest forecasted price for WVE Wave Life Sciences Ltd.?
The highest price target for WVE is $36.00 from Joon Lee at Truist Securities, which represents a 421.7% increase from the current price of $6.90.
What is the lowest forecasted price for WVE Wave Life Sciences Ltd.?
The lowest price target for WVE is $9.00 from at , which represents a 30.4% increase from the current price of $6.90.
What is the overall WVE consensus from analysts for Wave Life Sciences Ltd.?
The overall analyst consensus for WVE is bullish. Out of 16 Wall Street analysts, 12 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $21.00.
How accurate are WVE stock price projections?
Stock price projections, including those for Wave Life Sciences Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 2:37 PM UTC